Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Ranibizumab (Lucentis; Genentech), a humanized monoclonal antibody fragment that binds to vascular endothelial growth factor, was approved by the US FDA in June 2006 for the treatment of patients with neovascular age-related macular degeneration.
In June 2006, the tyrosine kinase inhibitor dasatinib (Sprycel; Bristol-Myers Squibb) was approved by the US FDA for the treatment of adults with chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia with resistance or intolerance to previous therapy, including the kinase inhibitor imatinib (Gleevec; Novartis).
In June 2006, a quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil; Merck) was approved by the US FDA for the prevention of several diseases, including cervical cancer, that are caused by these types of human papillomavirus.
Tipranavir (Aptivus; Boehringer Ingelheim) was given accelerated approval by the FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents in June 2005. It is the first in a new class of non-peptidic HIV-1 protease inhibitors, and is active against HIV-1 strains that are resistant to other protease inhibitors.
